The status of NIS as a relevant reporter gene for SPECT imaging in cancer gene therapy has been validated recently in phase 1 clinical trials using conditionally replicating adenovirus [24], [25], although vector design and dose are critical to the successful visualisation of transgene expression [26]. Here, SLC5A5 is linked to cancer.